Denali Therapeutics (DNLI) Earnings Date & Reports

Key Takeaways

• Denali Therapeutics is scheduled to report third-quarter 2026 results on Thursday, November 5, 2026, before the market opens.
• Consensus estimates point to a net loss of roughly $0.42 per share, with revenue projections centered near $23 million, though the range is unusually wide.
• Management has guided third-quarter product revenue from AVLAYAH to $10 million to $12 million, making the commercial launch ramp the central metric.
• The comparison is favorable: a year ago, Denali posted a $0.74 per-share loss with essentially no product revenue.
• Beyond sales, investors will watch payer coverage, cash runway, and updates on the Phase III COMPASS study and earlier-stage Alzheimer's programs.
• The company ended the second quarter with roughly $940 million in cash, later boosted above $1.1 billion by a priority review voucher sale.

Earnings Context and Why It Matters

Denali Therapeutics is a clinical- and commercial-stage biopharmaceutical company that engineers therapies to cross the blood-brain barrier (BBB, the protective layer surrounding the brain) to treat neurodegenerative and lysosomal storage diseases. Its lead medicine, AVLAYAH (tividenofusp alfa), was approved by the U.S. Food and Drug Administration (FDA) for MPS II (mucopolysaccharidosis type II, also known as Hunter syndrome), and the third quarter marks one of the earliest reads on how that launch is unfolding. For a company long defined by research spending and collaboration revenue, these results are a test of whether it can convert a first commercial product into durable top-line growth while continuing to advance a deep pipeline.

Earnings Expectations

For the third quarter of 2026, Wall Street's consensus calls for a net loss of roughly $0.42 per share (EPS, or earnings per share), though individual analyst estimates range from a notably smaller loss to a much wider one. Revenue consensus sits near $23 million, but projections vary considerably because of uncertainty around collaboration and milestone timing.

The clearest benchmark, however, is Denali's own guidance. Management told investors to expect $10 million to $12 million in third-quarter product revenue as the AVLAYAH launch ramps. A year ago, the company reported a $0.74 per-share loss with essentially no product revenue, so any meaningful sales figure represents a clear step change.

Historically, Denali has beaten consensus EPS in five of its last eight quarters. Its most recent report, the second quarter of 2026, delivered a $0.68 per-share loss alongside $3.6 million in revenue, AVLAYAH's first full commercial quarter. That print highlighted the early-stage nature of the launch and underscored the importance of the guided ramp investors will now be checking against.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotech names like Denali Therapeutics ahead of earnings, it offers a structured way to surface technical and fundamental setups across the sector. Explore the AI Screener to build your own watchlist.

Market Reaction and Investor Sentiment

Sentiment heading into the print is cautiously optimistic but mixed. Denali shares have climbed sharply over the past year as investors anticipated the AVLAYAH approval and launch, yet the stock has retraced some of those gains since the August report, when a wider-than-expected loss and revenue that landed below consensus briefly tested confidence. Management's decision to guide third-quarter product revenue to $10 million to $12 million refocused attention on launch execution rather than near-term profitability.

Key risk factors heading into earnings include the pace of patient starts and payer coverage for AVLAYAH, potential milestone or collaboration timing that could swing reported revenue, and the inherent volatility of clinical-stage news flow. Investors will likely reward evidence that the launch is tracking in line with guidance, while any shortfall or cautious commentary could renew pressure on the stock.

Forward Outlook and Key Factors to Monitor

The most important near-term variable is the AVLAYAH commercial trajectory. Investors will look beyond the headline loss to track reported product revenue against the $10 million to $12 million guide, along with commentary on payer coverage and patient demand. The company has said it secured coverage for more than 50% of covered lives, and any update on that figure will signal how quickly reimbursement is broadening.

Pipeline progress remains a second pillar. The Phase III COMPASS study, expected to run through 2027, underpins potential label expansion, while Denali's Alzheimer's programs, DNL628 and DNL921, are slated to report data in 2027. Any timeline adjustments or early signals could influence sentiment well before those readouts.

Finally, balance sheet and spending will matter. With roughly $1.1 billion in cash following a priority review voucher (PRV, a transferable asset granted for certain drug approvals) sale, Denali has a multi-year runway to fund the launch and late-stage development. Still, rising commercial and research costs mean investors should watch expense growth and any updated cash guidance for signs of how long that runway lasts.

Together, these factors make the third-quarter report less about a single bottom-line number and more about whether the launch is building momentum as Denali transitions toward becoming a fully commercial biotech.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations